SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Feb. 7, 2019--
Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage
biotechnology company focused on discovering and developing innovative
immuno-oncology protein therapeutics, will report its fourth quarter and
full year 2018 financial results on Tuesday, February 26, 2019, after
the U.S. financial markets close. Five Prime will host a conference call
and live audio webcast on Tuesday, February 26, 2019 at 4:30 p.m.
(ET)/1:30 p.m. (PT) to discuss the company's financial results and
provide a general business update.
The live audio webcast may be accessed through the "Events &
Presentations" page in the "Investors" section of the company's website
Alternatively, participants may dial (877) 878-2269 (domestic) or (253)
237-1188 (international) and refer to conference ID: 9689855.
The archived conference call will be available on Five Prime's website
beginning approximately two hours after the event and will be archived
and available for replay for at least 30 days after the event.
About Five Prime Therapeutics
Five Prime Therapeutics, Inc. discovers and develops innovative
therapeutics to improve the lives of patients with serious diseases.
Five Prime's comprehensive discovery platform, which encompasses
virtually every medically relevant extracellular protein, positions it
to explore pathways in cancer, inflammation and their intersection in
immuno-oncology, an area with significant therapeutic potential and the
focus of the company's R&D activities. Five Prime has entered into
strategic collaborations with leading global pharmaceutical companies
and has promising product candidates in clinical and late preclinical
development. For more information, please visit www.fiveprime.com
or follow us on LinkedIn,
View source version on businesswire.com: https://www.businesswire.com/news/home/20190207005793/en/
Source: Five Prime Therapeutics, Inc.
VP, Investor Relations & Corporate Communications
Prime Therapeutics, Inc.